OpenURL Connection Search

Select item for more details and to access through your institution.

CYP3A5*3 and CYP3A4*22 Cluster Polymorphism Effects on LCP-Tac Tacrolimus Exposure: Population Pharmacokinetic Approach.
Published in:
Pharmaceutics, 2023, v. 15, n. 12, p. 2699, doi. 10.3390/pharmaceutics15122699
By:
- Mohammed Ali, Zeyar;
- Meertens, Marinda;
- Fernández, Beatriz;
- Fontova, Pere;
- Vidal-Alabró, Anna;
- Rigo-Bonnin, Raul;
- Melilli, Edoardo;
- Cruzado, Josep M.;
- Grinyó, Josep M.;
- Colom, Helena;
- Lloberas, Nuria
Publication type:
Article
Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology – an analysis of the closed cohorts of a multicentre prospective study.
Published in:
British Journal of Cancer, 2024, v. 131, n. 5, p. 843, doi. 10.1038/s41416-024-02789-2
By:
- van der Kleij, Maud B. A.;
- Guchelaar, Niels A. D.;
- Meertens, Marinda;
- Westerdijk, Kim;
- Giraud, Eline L.;
- Bleckman, Roos F.;
- Groenland, Stefanie L.;
- van Eerden, Ruben A. G.;
- Imholz, Alex L. T.;
- Vulink, Annelie J. E.;
- Otten, Hans-Martin;
- Fiebrich-Westra, Helle-Brit;
- Lubberman, Floor J. E.;
- Desar, Ingrid M. E.;
- Moes, Dirk-Jan A. R.;
- Touw, Daan J.;
- Koolen, Stijn L. W.;
- Gelderblom, Hans;
- Reyners, An K. L.;
- van Erp, Nielka P.
Publication type:
Article
Evaluating the Clinical Impact and Feasibility of Therapeutic Drug Monitoring of Pazopanib in a Real-World Soft-Tissue Sarcoma Cohort.
Published in:
Clinical Pharmacokinetics, 2024, v. 63, n. 7, p. 1045, doi. 10.1007/s40262-024-01399-8
By:
- Meertens, Marinda;
- Giraud, Eline L.;
- van der Kleij, Maud B. A.;
- Westerdijk, Kim;
- Guchelaar, Niels A. D.;
- Bleckman, Roos F.;
- Rieborn, Amy;
- Imholz, Alex L. T;
- Otten, Hans-Martin;
- Vulink, Annelie;
- Los, Maartje;
- Hamberg, Paul;
- van der Graaf, Winette T. A.;
- Gelderblom, Hans;
- Moes, Dirk Jan A. R.;
- Broekman, K. Esther;
- Touw, Daan J.;
- Koolen, Stijn L. W.;
- Mathijssen, Ron H. J.;
- Huitema, Alwin D. R.
Publication type:
Article
Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC).
Published in:
Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1136221
By:
- Meertens, Marinda;
- Muntinghe-Wagenaar, M. Benthe;
- Sikkema, Barend J.;
- Lopez-Yurda, Marta;
- Retèl, Valesca P.;
- Paats, Marthe S.;
- Heine, Rob Ter;
- Schuuring, Ed;
- Timens, Wim;
- Touw, Daan J.;
- van Boven, Job F. M.;
- de Langen, Adrianus. J.;
- Hashemi, Sayed M. S.;
- Hendriks, Lizza E. L.;
- Croes, Sander;
- van den Heuvel, Michel M.;
- Dingemans, Anne-Marie C.;
- Mathijssen, Ron H. J.;
- Smit, Egbert F.;
- Huitema, Alwin D. R.
Publication type:
Article

Found: 4

CYP3A53 and CYP3A422 Cluster Polymorphism Effects on LCP-Tac Tacrolimus Exposure: Population Pharmacokinetic Approach.

Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology – an analysis of the closed cohorts of a multicentre prospective study.

Evaluating the Clinical Impact and Feasibility of Therapeutic Drug Monitoring of Pazopanib in a Real-World Soft-Tissue Sarcoma Cohort.

Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC).

Found: 4

CYP3A5*3 and CYP3A4*22 Cluster Polymorphism Effects on LCP-Tac Tacrolimus Exposure: Population Pharmacokinetic Approach.

Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology – an analysis of the closed cohorts of a multicentre prospective study.

Evaluating the Clinical Impact and Feasibility of Therapeutic Drug Monitoring of Pazopanib in a Real-World Soft-Tissue Sarcoma Cohort.

Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC).

CYP3A53 and CYP3A422 Cluster Polymorphism Effects on LCP-Tac Tacrolimus Exposure: Population Pharmacokinetic Approach.